David Moatazedi, CEO of Evolus, has set an ambitious target to increase the sales of Jeuveau, a botulinum toxin product by Daewoong Pharmaceutical, to $700 million in the US by 2028. Moatazedi expressed confidence in achieving this goal during his visit to Daewoong Pharmaceutical's production facility in Korea. He highlighted Jeuveau's rapid growth in the US market, reaching a 12 percent market share and emphasized the company's focus on branding and marketing to the younger demographic. Evolus, as Daewoong Pharmaceutical's US partner, has been selling Jeuveau since 2019 and aims to expand its presence in other countries. The company plans to launch Jeuveau in Australia and Spain this year, in addition to its current sales in the UK, Germany, Austria, and Italy under the brand name Nuceiva. Both companies are committed to strengthening their collaboration and pursuing mutual growth by exploring additional indications for Jeuveau and accelerating its global market launches. Daewoong Pharmaceutical foresees an average annual growth rate of approximately 20 percent for its botulinum toxin product until 2030.